On June 4, Centene rose 5.14% in regular trading, trading at $63.40/share, with trading volume of $59.48 million. The stock benefited from consecutive analyst target price upgrades amid broad strength across the Managed Health Care sector.

On the news front, Morgan Stanley raised its target price on Centene from $50 to $57 while maintaining an Equal Weight rating. Earlier, Truist had raised its target price from $58 to $71, maintaining a Buy rating. According to FactSet, the consensus average rating on Centene stands at Overweight with a mean price target of $59.76, suggesting analysts broadly view the stock favorably following its recent earnings report in late April which posted EPS of $3.37.

Within the Managed Health Care sector, the broader group rallied significantly. Among peers, Alignment Healthcare rose 8.56%, Humana rose 6.65%, UnitedHealth rose 5.96%, Molina Healthcare rose 4.83%, and Elevance Health rose 4.65%, indicating sector-wide tailwinds supporting today's move.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)